For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
Blog
Double Trouble Not Double the Fun with Medicare and Medicaid
There are 9.7 million people that use both Medicare and Medicaid for their health care expenses, according to a June 27 article in The Wall…
Citation
Greg Conko on FDA Approval for Avastin
CEI Senior Fellow Greg Conko discusses the FDA's pending decision on whether or not to withdraw its approval of Avastin as a treatment for breast…
Comment
CEI Submits Comments on the Proposed Inspection System for Catfish
Full Document Available as a PDF The Competitive Enterprise Institute…
The Wall Street Journal
Why Your New Car Doesn’t Have a Spare Tire
Auto makers comply with fuel economy mandates by making cars lighter and more dangerous. Fewer tires, higher taxes. That may be what’s in store for…
Blog
Meet Your New Mom: Kathleen Sebelius and Cigarette Warnings
Health and Human Services Director Kathleen Sebelius recently made a revealing statement on how she perceives the role of government and her place within…
The Wall Street Journal
There’s No ‘Average’ Cancer Patient
On June 28, the Food and Drug Administration (FDA) will hold a hearing to decide the fate of Avastin, a drug taken by thousands…